Alexandra GaubertTina KaussMathieu MarchivieBoubakar B. BaMartine LembegeFawaz FawazJean Michel BoironXavier LafargeNiklas LindegardhJean Louis FabreNicholas J. WhitePiero L. OlliaroPascal MilletKaren GaudinDeveloppements Analytiques et Pharmaceutiques Appliques aux Maladies Negligees et Aux ContrefaconsUniversite de BordeauxEtablissement Francais du SangMahidol UniversityOTECI (Office Technique d'Etude et de Coopération Internationale)Nuffield Department of Clinical MedicineOrganisation Mondiale de la Sante2018-11-092018-11-092014-07-01International Journal of Pharmaceutics. Vol.468, No.1-2 (2014), 55-6318733476037851732-s2.0-84899424141https://repository.li.mahidol.ac.th/handle/20.500.14594/34901Artemether (AM) plus azithromycin (AZ) rectal co-formulations were studied to provide pre-referral treatment for children with severe febrile illnesses in malaria-endemic areas. The target profile required that such product should be cheap, easy to administer by non-medically qualified persons, rapidly effective against both malaria and bacterial infections. Analytical and pharmacotechnical development, followed by in vitro and in vivo evaluation, were conducted for various AMAZ coformulations. Of the formulations tested, stability was highest for dry solid forms and bioavailability for hard gelatin capsules; AM release from AMAZ rectodispersible tablet was suboptimal due to a modification of its micro-crystalline structure. © 2014 The Authors.Mahidol UniversityPharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1016/j.ijpharm.2014.04.023